InspireMD Reports First Quarter 2026 Financial Results
Rhea-AI Summary
InspireMD (Nasdaq: NSPR) reported Q1 2026 revenue of $3.4 million, up 122% year‑over‑year, with U.S. revenue of $1.2 million and international revenue of $2.2 million. Gross profit was $0.7 million (20.2% margin); adjusted gross profit was $1.2 million (34.1%) excluding a $0.5 million inventory impairment. Net loss was $13.7 million, or $0.16 per share. The company received FDA IDE approval for the CGUARDIANS III trial of SwitchGuard NPS for TCAR and expects FDA actions on CGuard delivery systems in Q3 and H2 2026. A voluntary recall of CGuard Prime 135 cm may affect short‑term availability and has expected reserves of ~$700k returns and ~$650k remediation.
Positive
- Revenue +122% YoY to $3.4M in Q1 2026
- U.S. revenue +36% QoQ to $1.2M
- IDE approval received for CGUARDIANS III trial of SwitchGuard NPS
- Adjusted gross margin 34.1% excluding $0.5M impairment
Negative
- Net loss $13.7M in Q1 2026
- Operating expenses increased to $14.7M (+$2.9M YoY)
- Voluntary recall of CGuard Prime 135 cm affects short‑term availability
- Expected reserves for recall: ~$700k customer returns and ~$650k remediation
Key Figures
Market Reality Check
Peers on Argus
NSPR was down 2.54% while several device peers like BDMD, ICAD and RCEL showed single-digit gains. With no peers in the momentum scanner and mixed moves across the group, today’s action appears stock-specific rather than sector-driven.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 18 | Q4/FY 2025 earnings | Positive | +0.0% | Reported strong Q4 revenue growth, improved gross margin, and 2026 guidance. |
| Nov 04 | Q3 2025 earnings | Negative | -7.2% | Revenue growth but sharply higher operating expenses and wider net loss post U.S. launch. |
| Aug 05 | Q2 2025 earnings | Negative | -8.2% | Net loss and major equity financing despite FDA approval and launch milestones. |
| May 09 | Q1 2025 earnings | Negative | +0.0% | Minimal revenue growth with significantly higher operating expenses and wider losses. |
| Mar 12 | Q4/FY 2024 earnings | Neutral | +0.7% | Record quarterly revenue but lower gross margin and higher operating expenses. |
Earnings and financial updates have typically led to flat-to-negative next-day moves, even when revenue growth and approvals were highlighted.
Over the past year, earnings releases for InspireMD have shown consistent revenue growth, expanding U.S. commercialization of CGuard Prime, and advancing pivotal trials, yet price reactions have often been muted or negative. Prior updates highlighted FDA approval and U.S. launch of CGuard Prime, equity raises, and rising operating expenses as the company scaled its U.S. presence. Today’s Q1 2026 results, with strong 122% revenue growth and IDE clearance for CGUARDIANS III, continue this pattern of operational progress alongside sustained investment and losses.
Historical Comparison
In the last five earnings releases, NSPR’s average move was about -2.95%, with reactions often flat to negative despite revenue growth. Today’s earnings update fits into this pattern of cautious trading.
Earnings releases show progression from early CGuard Prime FDA engagement to full U.S. approval and commercialization, growing revenue from sub-$2M quarters to above $3M, alongside expanded trials in TCAR.
Regulatory & Risk Context
The company has an active S-3 shelf registration filed on 2025-08-06, with at least one usage via a 424B5 prospectus supplement dated 2026-04-03. This framework allows periodic issuance of securities subject to market conditions and corporate needs.
Market Pulse Summary
This announcement highlights a sharp acceleration in revenue to $3.4 million in Q1 2026, up 122% year-over-year, alongside FDA IDE approval for the CGUARDIANS III trial and expectations for multiple U.S. approvals in 2026. At the same time, the company reported a net loss of $13.7 million and outlined recall-related reserves totaling about $1.35 million. Investors may focus on execution of the TCAR strategy, progress on upcoming FDA decisions, and how operating expenses evolve relative to growth.
Key Terms
investigational device exemption regulatory
ide regulatory
transcarotid artery revascularization medical
non-gaap financial
AI-generated analysis. Not financial advice.
- Reports total Q1 2026 revenue of
- Received IDE approval from FDA to initiate the CGUARDIANS III clinical trial of its SwitchGuard neuro protection system for use in TCAR procedures -
- FDA approval of the original CGuard delivery system anticipated in Q3 2026 -
- On track for expected FDA approval of the CGuard Prime 80 cm for TCAR procedures in H2 2026, potentially doubling the Company’s addressable market -
MIAMI, May 04, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the first quarter ended March 31, 2026.
Recent Business Highlights:
- Generated revenue of
$3.4 million in the first quarter of 2026, up122% year-over-year, with significant growth in demand for CGuard Prime in the U.S. and original CGuard in international markets. - Supported over 625 cumulative carotid procedures utilizing CGuard Prime across over 100 leading U.S. hospitals and integrated delivery networks since launch.
- Filed for and anticipate FDA approval of the original, clinically proven CGuard stent delivery system in Q3 2026.
- Received Investigational Device Exemption (“IDE”) approval from the FDA to initiate the CGUARDIANS III clinical trial that will evaluate the Company’s next-generation SwitchGuard neuro protection system (“NPS”) with CGuard Prime 80 cm for use in transcarotid artery revascularization (“TCAR”) procedures.
- Initiated a voluntary recall of CGuard Prime 135 cm carotid stent delivery system to address the need for technical enhancements to improve user experience and delivery system performance.
“Our first quarter results reflect strong underlying demand and consistent clinical outcomes for our CGuard carotid stent implant both in the U.S. and internationally,” stated Marvin Slosman, Chief Executive Officer of InspireMD. “While our decision to voluntarily pause commercialization of CGuard Prime 135 cm in the U.S. will impact its availability in the short term, we are in the process of implementing several enhancements to the delivery system that we are confident will elevate technical performance and accelerate rapid adoption. Importantly, our TCAR program is unaffected by this voluntary action, and we were also pleased to have recently received FDA approval to initiate the CGUARDIANS III clinical trial with our SwitchGuard NPS, which, if successful, would enable us to offer a full TCAR tool kit leveraging our best-in-class implant.”
“In parallel, we are pursuing FDA approval of our commercially-proven CGuard stent delivery system which we anticipate in the third quarter of 2026. This delivery system was successfully used in over 70,000 implants globally. Having this additional delivery system available in the U.S. will enable us to offer physicians multiple options to deliver the best implant to their patients,” Mr. Slosman concluded.
Financial Results for the First Quarter Ended March 31, 2026
For the first quarter of 2026, total revenue was
U.S. revenue for the first quarter of 2026 was
Gross profit for the first quarter of 2026 was
Total operating expenses for the first quarter of 2026 were
Financial income, net, for the first quarter of 2026 was
Net loss for the first quarter of 2026 was
The Company currently expects the financial impact of the U.S. recall of CGuard Prime to include a reserve for customer returns of approximately
Conference Call and Webcast Details
Management will host a conference call at 4:30 pm ET today, May 4th, to review financial results and provide an update on corporate developments. Following management’s formal remarks, there will be a question-and-answer session. A live audio webcast and an archive of the recording will be available here and through the Investors page of InspireMD’s corporate website at https://investors.inspiremd.com.
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet™ mesh technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on Nasdaq under the ticker symbol NSPR. We routinely post information that may be important to investors on the Company’s website. For more information, please visit www.inspiremd.com.
Forward-looking Statements
This press release contains “forward-looking statements.” Forward-looking statements include, but are not limited to, statements regarding InspireMD or its management team’s expectations, hopes, beliefs, intentions or strategies regarding future events, future financial performance, strategies, expectations, competitive environment and regulation. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential”, “scheduled” or similar words. In particular, forward-looking statements in this press release include the Company’s expectations regarding potential FDA approvals for original CGuard and the CGuard Prime 80 cm stent for TCAR procedures, the Company’s expectations regarding enhancements to the CGuard Prime 135 cm delivery system, the Company’s beliefs regarding the potential adoption of its products, statements relating to the Company’s addressable markets and the Company’s expectations regarding reserves for customer returns and inventory impairment and remediation as result of the U.S. recall of CGuard Prime. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with the voluntary U.S. recall of the CGuard Prime 135 cm delivery system, including current and future costs associated with the recall, including refunds or inventory write-off costs and other remediation costs, loss of sales and customers due to the recall or otherwise, our ability to effectively implement enhancements to CGuard Prime 135 cm delivery system, potential actions by regulators or other governmental entities associated with the recall, potential claims and lawsuits by customers and patients, including class action product liability lawsuits, other operational impacts and consequences of the recall, such as business disruption and distraction of management and other key employees; the Company’s history of recurring losses and negative cash flows from operating activities, significant future commitments and the uncertainty regarding the adequacy of its liquidity to pursue its complete business objectives, and substantial doubt regarding its ability to continue as a going concern; the Company’s need to raise additional capital to meet its business requirements in the future and such capital raising may be costly or difficult to obtain and could dilute out stockholders’ ownership interests; the clinical development, commercialization and market acceptance of the Company’s products; whether the clinical trial results for the Company’s products will be predictive of real-world results; an inability to secure and maintain regulatory approvals for the sale of the Company’s products; negative clinical trial results or lengthy product delays in key markets; the Company’s ability to maintain compliance with the Nasdaq listing standards; the Company’s ability to generate significant revenues from its products; estimates of the Company’s expenses, future revenues, capital requirements and its needs for and ability to access sufficient additional financing, including any unexpected costs or delays in the ongoing commercial launch of its products; the Company’s dependence on a single manufacturing facility and its ability to comply with stringent manufacturing quality standards and to increase production as necessary; the risk that the data collected from the Company’s current and planned clinical trials may not be sufficient to demonstrate that its technology is an attractive alternative to other procedures and products; intense competition in the Company’s industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than it does; entry of new competitors and products and potential technological obsolescence of the Company’s products; inability to carry out research, development and commercialization plans; loss of a key customer or supplier; technical problems with the Company’s research and products and potential product liability claims; product malfunctions; price increases for supplies and components; whether access to the Company’s products is achieved in a commercially viable manner and whether its products receive adequate reimbursement by governmental and other third-party payers; the Company’s efforts to successfully obtain and maintain intellectual property protection covering its products, which may not be successful; adverse federal, state and local government regulation, in the United States, Europe or Israel and other foreign jurisdictions; the fact that the Company conducts business in multiple foreign jurisdictions, exposing it to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction; security, political and economic instability in the Middle East that could harm the Company’s business, including due to the current security situation in Israel; current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; and changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements and the impact of such policies on the Company, its customers and suppliers, and the global economic environment. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Non-GAAP Financial Measures
To supplement its consolidated financial statements, which are prepared and presented in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”), this press release and the accompanying tables include supplemental financial information, referred to as non-GAAP financial measure, that have not been prepared in accordance GAAP, including adjusted gross profit. The Company believes that the use of non-GAAP accounting measures is useful to its investors as an additional tool to enhance the overall understanding of past financial performance and future prospects, and allow for greater transparency with respect to key measures used by management in its financial and operational decision making. The Company defines adjusted gross profit as gross profit excluding the impact of the reserve for inventory impairment recognized during the period.
The non-GAAP financial data are not measures of the Company’s financial performance under GAAP and should not be considered as alternatives to gross margin or any other performance measures derived in accordance with GAAP. Non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in other industries or within InspireMD’s industry, as other companies may calculate non-GAAP financial results differently, particularly related to non-recurring, unusual items. In addition, there are limitations in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance with GAAP, may be different from non-GAAP financial measures used by other companies and exclude expenses that may have a material impact on the Company’s reported financial results. Further, the reserve for inventory impairment recognized during the period is a significant item that affects gross profit and may obscure the Company’s underlying operating performance and comparability between periods.
The presentation of non-GAAP financial information is not meant to be considered in isolation, as a substitute for, or superior to the directly comparable financial measures prepared in accordance with GAAP. In addition, non-GAAP measures should not be construed as an inference that the Company’s future results will be unaffected by unusual or non-recurring items. InspireMD urges investors to review the financial results calculated in accordance with GAAP and the reconciliation of the Company’s non-GAAP financial measures to the comparable GAAP financial measures included below, and not to rely on any single financial measure to evaluate the Company’s business.
Investor Contacts:
Jeff Warren
LifeSci Advisors
jwarren@lifesciadvisors.com
investor-relations@inspiremd.com
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(1)
(Unaudited)
(U.S. dollars in thousands, except share and per share data)
| Three months ended | |||||
| March 31, | |||||
| 2026 | 2025 | ||||
| Revenues | $ | 3,398 | $ | 1,529 | |
| Cost of revenues | 2,711 | 1,237 | |||
| Gross Profit | 687 | 292 | |||
| Operating Expenses: | |||||
| Research and development | 4,763 | 4,059 | |||
| Selling and marketing | 5,180 | 2,750 | |||
| General and administrative | 4,722 | 4,943 | |||
| Total operating expenses | 14,665 | 11,752 | |||
| Loss from operations | (13,978) | (11,460) | |||
| Financial Income, net | 289 | 294 | |||
| Net Loss | $ | (13,689) | $ | (11,166) | |
| Net loss per share – basic and diluted | $ | (0.16) | $ | (0.22) | |
| Weighted average number of common stock used in computing net loss per share – basic and diluted | 83,801,839 | 49,993,509 | |||
| CONDENSED CONSOLIDATED BALANCE SHEETS (2) (Unaudited) | |||||
| (U.S. dollars in thousands other than share and per share data) | |||||
| ASSETS | March 31, | December 31, | |||
| 2026 | 2025 | ||||
| Current Assets: | |||||
| Cash and cash equivalents | $ | 11,362 | $ | 8,939 | |
| Marketable securities | 30,208 | 45,272 | |||
| Accounts receivable: | |||||
| Trade, net | 2,381 | 2,168 | |||
| Other | 407 | 400 | |||
| Prepaid expenses | 1,200 | 1,296 | |||
| Inventory | 3,036 | 3,396 | |||
| Total current assets | 48,594 | 61,471 | |||
| Non-current assets: | |||||
| Long term deposit | 446 | 442 | |||
| Property, plant and equipment, net | 3,651 | 3,584 | |||
| Operating lease right of use assets | 2,595 | 2,758 | |||
| Funds in respect of employee rights upon retirement | 1,185 | 1,149 | |||
| Total non-current assets | 7,877 | 7,933 | |||
| Total assets | $ | 56,471 | $ | 69,404 | |
| LIABILITIES AND EQUITY | March 31, | December 31, | |||
| 2026 | 2025 | ||||
| Current liabilities: | |||||
| Accounts payable and accruals: | |||||
| Trade | $ | 1,954 | $ | 1,255 | |
| Other | 7,489 | 9,457 | |||
| Total current liabilities | 9,443 | 10,712 | |||
| Long-term liabilities: | |||||
| Operating lease liabilities net of current maturities | 2,042 | 2,224 | |||
| Liability for employee rights upon retirement and others | 1,369 | 1,267 | |||
| Total long-term liabilities | 3,411 | 3,491 | |||
| Total liabilities | $ | 12,854 | $ | 14,203 | |
| COMMITMENTS AND CONTINGENT LIABILITIES | |||||
| Equity: | |||||
| Common stock, par value | 4 | 4 | |||
| Preferred C shares, par value 1,172,000 shares authorized at March 31, 2026 and December 31, 2025; 1,718 shares issued and outstanding at March 31, 2026 and December 31, 2025 | * | * | |||
| Additional paid-in capital | 359,594 | 357,489 | |||
| Accumulated deficit | (315,981) | (302,292) | |||
| Total equity | 43,617 | 55,201 | |||
| Total liabilities and equity | $ | 56,471 | $ | 69,404 | |
(1) All 2026 financial information is derived from the Company’s 2026 unaudited financial statements, as disclosed in the Company’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission; all 2025 financial information is derived from the Company’s 2025 unaudited financial statements, as disclosed in the Company’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission.
(2) All March 31, 2026 financial information is derived from the Company’s 2026 unaudited financial statements, as disclosed in the Company’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission. All December 31, 2025 financial information is derived from the Company’s 2025 audited financial statements as disclosed in the Company’s Annual Report on Form 10-K, for the twelve months ended December 31, 2025 filed with the Securities and Exchange Commission.
Adjusted Gross Profit
The following table reconciles Adjusted Gross Profit to Gross Profit, which we consider to be the most directly comparable GAAP financial measure
| Three Months Ended | ||||||||
| March 31, 2026 | March 31, 2025 | |||||||
| Dollars in thousands | $ % of revenues | $ % of revenues | ||||||
| Gross profit | $ | 687 | | $ | 292 | | ||
| Adjustments: | ||||||||
| Inventory impairment charge | $ | 473 | - | - | ||||
| Adjusted gross profit | $ | 1,160 | | $ | 292 | | ||
